SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001720725-21-000041
Filing Date
2021-05-06
Accepted
2021-05-06 16:04:44
Documents
50
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q oyst-20210331.htm   iXBRL 10-Q 729093
2 EX-31.1 oyst-q1x21ex311.htm EX-31.1 12975
3 EX-31.2 oyst-q1x21ex312.htm EX-31.2 12988
4 EX-32.1 oyst-q1x21ex321.htm EX-32.1 7887
5 EX-32.2 oyst-q1x21ex322.htm EX-32.2 7882
  Complete submission text file 0001720725-21-000041.txt   3724448

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20210331.xsd EX-101.SCH 26173
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oyst-20210331_cal.xml EX-101.CAL 72732
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oyst-20210331_def.xml EX-101.DEF 65680
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20210331_lab.xml EX-101.LAB 378423
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20210331_pre.xml EX-101.PRE 229188
11 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20210331_htm.xml XML 571041
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39112 | Film No.: 21897652
SIC: 2836 Biological Products, (No Diagnostic Substances)